Integra Lifesciences Holdings Corp.
IARTHIGH VELOCITYFILING INTENSITYIntegra Lifesciences Holdings Corp. reads as an High Velocity (composite 78/100); Consistent Strategic Buyer deploying $2B across 4 disclosed transactions, up 206% vs the prior cycle · primary market Life Sciences, ranked #11 on disclosed spend.
Lens
Disclosed M&A capital (2023–2025)
$2.2B
vs $715M in 2020–2022
Disclosed transactions
4
2/3 active fiscal years in window
Buyer archetype
Consistent Strategic Buyer
Meaningful spend appears across repeat years.
Composite score
78
High Velocity dominates · Filing Intensity
Behavioral posture, nine reads.
Each index scores the issuer 0–100 against an EDGAR-anchored definition. Scores ≥ threshold elevate the issuer into the index's constituent set; the dominant index drives the masthead label.
Active Acquirer
Companies actively deploying disclosed capital into M&A
- $6.2B disclosed buyer spend
- Filed within 18d
Buyer Cadence
Buyer-side companies with recent filing activity
- Filed within 18d
- 413 8-Ks
Target Probability
Issuers showing target-side patterns from filings
- 25 activism filings
Spin/Carve
Issuers showing spin-off, carve-out, or sum-of-parts posture
- 25 activism filings
Pressure Watch
Issuers facing activism, governance, or control pressure
- 25 activism filings
- Latest activism 11y ago; heavily discounted
Distress Watch
Issuers showing financial-distress filing patterns
- 25 activism filings
Restatement Risk
Issuers with accounting-integrity flags from filings
Capital Velocity
DominantIssuers with the highest filing-activity intensity
- 413 8-Ks
- Filed within 18d
- 5 form types
Quiet Power
Large issuers with low signal volume and clean disclosure cadence
- Enterprise value $2.9B
- 10-Q 21d ago
- 2 active signals
Capital cadence.
Ten-year disclosed M&A activity. Bars show spend ($MM); ticks show recorded transaction count. Disclosure tier annotated where v6 audited corpus carries an entry.
Disclosed spend $MM Disclosed transactions (right axis)Peak spend year: $2,187M · Peak count: 7
| FY | Disclosed buys | Disclosed spend | Avg ticket | Audited tier |
|---|---|---|---|---|
| 2025 | 2 | $2.2B | $1.1B | N/A |
| 2024 | 2 | N/A | N/A | N/A |
| 2023 | N/A | N/A | N/A | N/A |
| 2022 | 1 | $52M | $52M | N/A |
| 2021 | N/A | $3M | N/A | N/A |
| 2020 | 2 | $660M | $330M | N/A |
Strategy posture.
The buyer's playbook in terms of strategic archetype: what each disclosed move says about how they're deploying capital.
Archetype mix
- Bolt On20%
- Geographic Expansion20%
- Platform20%
- Tuck In20%
- Horizontal Consolidation20%
Strategy keywords
Terms recurring across recent 10-K acquisition disclosures.
- bolt_on
- geographic_expansion
- platform
- tuck_in
- horizontal_consolidation
Filing language.
Direct excerpts from acquisition disclosures and strategy sections: the verbs the buyer chose, in the filings they signed.
“This acquisition not only expanded the Company’s product offering of regenerative technologies, but it also supported the Company’s long-term growth and profitability strategy as this product line has a financial profile similar to Integra’s other regenerative tissue products.”
“On December 6, 2022, the Company completed the acquisition of Surgical Innovation Associates, Inc. ("SIA"), which develops, markets and sells DuraSorb®, a resorbable synthetic matrix for plastic and reconstructive surgery.”
“This acquisition will advance Integra’s global strategy in breast reconstruction, expanding plans to access the U.S. market where SIA is pursuing pre-market approval for use in implant-based breast reconstruction ("IBBR").”
“In 2021, the Company acquired ACell Inc. ("ACell"), an innovative regenerative medicine company specializing in the manufacturing of porcine urinary bladder extracellular matrices.”
“expanding our capabilities in the U.S. ENT market”
Market context.
Where this issuer sits inside its SE-Cluster rollup wedge, with disclosed-spend rank plus trading comparables against the public peer set.
Primary market
Life Sciences
- Market spend (2023–2025)
- $68.3B
- Market spend (2020–2022)
- $107.5B
- Recent vs prior
- −36%
- Issuer rank in market
- #11 of 155
- Share of market capital
- 1.7%
Valuation positioning
IART trades at a -26.6-turn discount to the Life Sciences peer median of 16.1×.
- EV / Revenue
- 1.8×
- Net debt / EBITDA
- N/A
- Peer median EV / EBITDA
- 16.1×
Trading comparables
FMP market data · 2026-05-10
| Company | EV / EBITDA | EV / Rev | Net debt / EBITDA | Revenue | M&A 2023–2025 |
|---|---|---|---|---|---|
| 19.1× | 4.7× | -0.0× | $45.2B | $10.8B | |
| 18.8× | 4.3× | -0.3× | $20.6B | $8B | |
| 13.3× | 3.5× | -0.1× | $35.5B | $2.2B | |
| 13.1× | 1.9× | -0.2× | $14.1B | $2.1B |
Trading multiples from FMP market data; disclosed M&A spend from the SE-Cluster EDGAR 10-K corpus. Peer set = top disclosed buyers in Life Sciences. Bars scaled to the highest EV/EBITDA in the set.
Target landscape.
Public-issuer targets that fit this buyer's archetype and target categories from filing-derived signal. Scores reflect cross-signal fit; reasons cite the EDGAR-anchored facts that drove the match.
No qualifying public-issuer targets surfaced from the current signal mix.
Stated target categories
No target categories enumerated in the audited corpus for this issuer.
Filing activity & signal stream.
Filing cadence and event-driven signals visible on EDGAR. The signal stream below is curated from restatement / spin-carve / activism categories, providing context for any near-term call.
Filing cadence
- 10-K (annual)322026-02-26
- 10-Q (quarterly)922026-05-05
- 8-K (event)4132026-05-08
- Proxy / DEF 14A342026-05-05
- Activism (13D / DFAN / PREC)252015-05-11
Signals on file
- elevated
Activism on file
2015-05-1125 activist filings on file (13D, DFAN14A, PREC14A series).
- info
Signal
Serial acquisition history
- info
Signal
10-K strategy themes
Audited corpus.
No audited record on file for this CIK in the current v6 corpus.
This issuer has not been extracted into the v6 audited acquirer corpus yet. The brief above pulls from ranking-level aggregates and issuer-index signal only.